Baclofen for Spasticity in Multiple Sclerosis: Human Review Findings
A narrative review suggests baclofen, a GABA-B receptor agonist, is a recommended first-line oral treatment for spasticity in multiple sclerosis (MS) due to its effective long-term control without increasing sedation.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
The review highlights the potential benefits of baclofen for managing spasticity in MS, helping guide treatment strategies, though the findings rely on varied literature quality and types.
What this does not prove
The narrative nature of the review means findings may be biased due to non-systematic source selection and reliance on secondary data. The quality and design heterogeneity of the underlying studies also limits robustness.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-16
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceBaclofen for Spasticity in Multiple Sclerosis: A Comprehensive Narrative Review. ↗DOI: 10.3390/biomedicines14102357
Supporting passages (5)
publication datePublication date: 2026-10-16
findingsBaclofen, a GABA-B receptor agonist developed as an anticonvulsant in the 1960s and repurposed for spasticity in the 1970s, is recommended as a first-line oral treatment for spasticity in multiple sclerosis (MS) by UK NICE guidance and is used similarly, though not necessarily designated identically, in many other jurisdictions.
limitationsBecause this is a narrative rather than systematic review, source selection was not governed by a prespecified protocol, some clinical estimates rely on secondary or aggregate data, and the underlying literature is heterogeneous in design and quality.
peer reviewedPublication types: Journal Article; Review
subjectsWeighing benefit against harm, this review concludes that baclofen offers a net benefit, but conditionally: only for carefully selected, individually titrated, and actively monitored patients.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.